LYTIX: Research Council of Norway awards Lytix Biopharma NOK 12 million to extend its oncolytic platform to deep-seated tumors

Oslo, Norway, November 5, 2026 - Lytix Biopharma ASA ("Lytix" or the "Company"),
a clinical-stage immuno-oncology company developing novel intratumoral cancer
therapies, today announced that it has been awarded NOK 12 million by the
Research Council of Norway under the Innovation Project for the Industrial
Sector (IPN) scheme. The grant will fund the development of new formulations of
Lytix's oncolytic molecules designed for intratumoral injection.

IPN grants are awarded through a competitive national call in which applications
are assessed by independent experts on their degree of innovation, potential
impact and the applicant's ability to execute.

"We are very grateful to the Research Council of Norway for this grant. Being
selected to receive this grant is a strong recognition of the scientific quality
of our platform and of the work we do together with our research partners", said
Øystein Rekdal, CEO of Lytix Biopharma.

About Lytix Biopharma ASA
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotech company
with a highly differentiated oncolytic molecule platform based on world-leading
research in host-defense peptide-derived molecules. Lytix Biopharma's lead
product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule
representing a new approach to achieve durable anti-cancer immunity. Lytix
Biopharma has a pipeline of molecules with potential across multiple cancer
indications and treatment settings, both as monotherapy and in combination
therapy. Lytix Biopharma is listed on Euronext Growth Oslo under the ticker
symbol LYTIX.

For further information, please contact:
Gjest Breistein, CFO
E-mail: gjest.breistein@lytixbiopharma.com 

For more information, visit www.lytixbiopharma.com.
more information\, visit www.lytixbiopharma.com.\